drugset / Trial / NCT00473720

Phase I Study of the Combination of Satraplatin and Abraxane in Advanced Cancers

NCT00473720

Phase 1 Completed 15 enrolled Yale University Agennix · collab
NaSingle-groupOpen-labelTreatment

Summary

This is a phase I dose escalating study of oral satraplatin in combination with Abraxane administered weekly for three out of every four weeks in patients with advanced solid cancers.

Timeline

Start
2007-05
Primary completion
2010-06
Completion
2010-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Paclitaxel Small molecule 80 mg/m2
Subject Paclitaxel Small molecule 100 mg/m2
Subject Satraplatin Other / unclassified 40 mg/m2 Oral
Subject Satraplatin Other / unclassified 60 mg/m2 Oral
Subject Satraplatin Other / unclassified 80 mg/m2 Oral